- Home
- URGN vs GES Comparison
URGN vs GES Comparison
Compare URGN & GES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- GES
- Stock Information
- Founded
- URGN 2004
- GES 1981
- Country
- URGN United States
- GES Switzerland
- Employees
- URGN N/A
- GES N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- GES Apparel
- Sector
- URGN Health Care
- GES Consumer Discretionary
- Exchange
- URGN Nasdaq
- GES Nasdaq
- Market Cap
- URGN 830.4M
- GES 872.4M
- IPO Year
- URGN 2017
- GES 1996
- Fundamental
- Price
- URGN $20.62
- GES $16.98
- Analyst Decision
- URGN Strong Buy
- GES Buy
- Analyst Count
- URGN 8
- GES 5
- Target Price
- URGN $28.50
- GES $19.25
- AVG Volume (30 Days)
- URGN 921.6K
- GES 572.9K
- Earning Date
- URGN 11-06-2025
- GES 11-25-2025
- Dividend Yield
- URGN N/A
- GES 5.30%
- EPS Growth
- URGN N/A
- GES N/A
- EPS
- URGN N/A
- GES 0.35
- Revenue
- URGN $94,238,000.00
- GES $3,091,508,000.00
- Revenue This Year
- URGN $36.41
- GES $7.97
- Revenue Next Year
- URGN $118.04
- GES $3.46
- P/E Ratio
- URGN N/A
- GES $48.96
- Revenue Growth
- URGN 10.85
- GES 7.84
- 52 Week Low
- URGN $3.42
- GES $8.48
- 52 Week High
- URGN $21.71
- GES $18.07
- Technical
- Relative Strength Index (RSI)
- URGN 63.69
- GES 65.47
- Support Level
- URGN $19.17
- GES $16.75
- Resistance Level
- URGN $21.00
- GES $17.04
- Average True Range (ATR)
- URGN 1.12
- GES 0.08
- MACD
- URGN 0.35
- GES -0.03
- Stochastic Oscillator
- URGN 83.19
- GES 80.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.